Robert Howard, MD, MRCPsych; Olga Zubko, PhD; Rosie Bradley, MSc; et al.
open access
JAMA Neurol. 2020;77(2):164-174. doi:10.1001/jamaneurol.2019.3762
This randomized clinical trial examines whether 24 months of minocycline treatment can modify cognitive and functional decline in patients with mild Alzheimer disease.
Christopher A. Lane, MD, PhD; Josephine Barnes, PhD; Jennifer M. Nicholas, PhD; et al.
open access
JAMA Neurol. 2020;77(2):175-183. doi:10.1001/jamaneurol.2019.3774
This longitudinal cohort study assesses the associations between vascular risk in early adulthood, midlife, and late life with late-life brain structure and 尾-amyloid load and white matter hyperintensity, whole-brain, and hippocampal volumes.
Gustavo Luna, MSc; Peter Alping, MD; Joachim Burman, MD, PhD; et al.
free access
JAMA Neurol. 2020;77(2):184-191. doi:10.1001/jamaneurol.2019.3365
This registry-based cohort study examines the risk of serious infections associated with disease-modifying treatments for multiple sclerosis in Sweden.
Patrícia R. Faustino, MD; Gonçalo S. Duarte, MD; Inês Chendo, MD; et al.
free access
JAMA Neurol. 2020;77(2):192-198. doi:10.1001/jamaneurol.2019.3446
This systematic review and meta-analysis assesses the association of bipolar disorder with a later diagnosis of idiopathic Parkinson disease.
Alette M. Wessels, PhD; Pierre N. Tariot, MD; Jennifer A. Zimmer, MD; et al.
open access
has audio
JAMA Neurol. 2020;77(2):199-209. doi:10.1001/jamaneurol.2019.3988
The AMARANTH and DAYBREAK-ALZ randomized clinical trials assess whether lanabecestat slows the progression of Alzheimer disease compared with placebo in patients with early Alzheimer disease or mild Alzheimer disease dementia.
-
Podcast:
Efficacy and Safety of Lanabecestat for Treatment of Early and Mild Alzheimer Disease
Virgilio Hernández Ruiz, MD; Arlette Edjolo, PhD; Claire Roubaud-Baudron, MD, PhD; et al.
free access
JAMA Neurol. 2020;77(2):210-214. doi:10.1001/jamaneurol.2019.3292
This prospective cohort study examines the association between seropositivity to Borrelia burgdorferi and incidental neuropsychiatric disorders and functional decline in rural southwestern France.
Richard M. Tsai, MD; Zachary Miller, MD; Mary Koestler, PhD; et al.
free access
JAMA Neurol. 2020;77(2):215-224. doi:10.1001/jamaneurol.2019.3812
This parallel-design, double-blind randomized clinical trial assesses the safety, tolerability, and pharmacodynamics of the microtubule stabilizer TPI-287 in patients with Alzheimer disease or the 4-repeat tauopathies progressive supranuclear palsy and corticobasal syndrome.
Fadi S. Hanna Al-Shaikh, BS; Ranjan Duara, MD; Julia E. Crook, PhD; et al.
open access
JAMA Neurol. 2020;77(2):225-233. doi:10.1001/jamaneurol.2019.3606
This cross-sectional study using tissue from the Florida Autopsied Multi-Ethnic cohort assesses whether an association exists between neuropathologic subtypes of Alzheimer disease and neurofibrillary tangle accumulation or neuron loss in the nucleus basalis of Meynert, a major source of brain cholinergic innervation.
Magí Andorrà, MSc; Salut Alba-Arbalat, MSc; Anna Camos-Carreras, MD; et al.
free access
JAMA Neurol. 2020;77(2):234-244. doi:10.1001/jamaneurol.2019.3283
This cohort study comprehensively assesses key biological and methodologic aspects of trials of acute optic neuritis for testing neuroprotection and remyelination in multiple sclerosis.